Roivant Sciences Ltd.
41.81USD
+0.3300 (+0.80%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.45▼ | $-0.4 | 0 | 3 |
| Next quarter | $-0.41▼ | $-0.37 | 0 | 3 |
| Current year | $-1.58▼ | $-1.5 | 0 | 3 |
| Next year | $-1.72▼ | $-1.56 | 1 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.36 | $-0.34 | +0.02 (+4.9%) |
| 2026-03-31 | $-0.35 | $-0.32 | +0.03 (+9.3%) |
| 2025-12-31 | $-0.31 | $-0.24 | +0.07 (+23.0%) |
| 2025-09-30 | $-0.3 | $-0.28 | +0.03 (+9.3%) |
95 ratings from 16 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| TD Cowen | Maintained | Buy | $50 $55 | Sep 9, 2026 |
| Guggenheim | Maintained | Buy | $42 $46 | Sep 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $41 $47 | Sep 8, 2026 |
| Jefferies | Maintained | Buy | $42 $52 | Sep 8, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $41 | Aug 28, 2026 |
| Citigroup | Maintained | Buy | $42 $46 | Aug 10, 2026 |
| Guggenheim | Maintained | Buy | $36 $42 | Aug 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $34 $41 | Aug 7, 2026 |
| Guggenheim | Maintained | Buy | $30 $36 | May 26, 2026 |
| Citigroup | Maintained | Buy | $35 $42 | May 21, 2026 |
| TD Cowen | Maintained | Buy | $38 $41 | May 21, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $34 | May 21, 2026 |
| Piper Sandler | Maintained | Overweight | $22 $40 | Apr 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $33 $34 | Mar 4, 2026 |
| Citigroup | Maintained | Buy | $26 $35 | Feb 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $26 $33 | Feb 10, 2026 |
| Guggenheim | Maintained | Buy | $28 $30 | Feb 9, 2026 |
| Leerink Partners | Maintained | Outperform | $29 $32 | Dec 15, 2025 |
| Goldman Sachs | Maintained | Buy | $24 $33 | Dec 15, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $23 $26 | Dec 12, 2025 |
| Citigroup | Maintained | Buy | $25 $26 | Nov 11, 2025 |
| Citigroup | Maintained | Buy | $16 $25 | Oct 29, 2025 |
| Goldman Sachs | Maintained | Buy | $20 $24 | Sep 18, 2025 |
| Jefferies | Maintained | Buy | $18 $20 | Sep 18, 2025 |
| JP Morgan | Maintained | Overweight | $16 $20 | Sep 18, 2025 |
150 filings from 14 insiders · 22 buy / 17 sell over 6m
Officers and directors of ROIV, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| VENKER ERICPresident | Exercise | 200.0k | $3.85 | $770k | Aug 28, 2026 |
| VENKER ERICPresident | Sell | 200.0k | $35.63 | $7.15M | Aug 28, 2026 |
| SUKHATME MAYUKHPresident | Exercise | 335.2k | $3.85 | $1.29M | Aug 21, 2026 |
| SUKHATME MAYUKHPresident | Sell | 335.2k | $36.48 | $12.36M | Aug 21, 2026 |
| SUKHATME MAYUKHPresident | Exercise | 664.8k | $3.85 | $2.56M | Aug 18, 2026 |
| SUKHATME MAYUKHPresident | Sell | 664.8k | $36.23 | $24.16M | Aug 18, 2026 |
| VENKER ERICPresident | Exercise | 200.0k | $3.85 | $770k | Jul 27, 2026 |
| VENKER ERICPresident | Sell | 200.0k | $34.95 | $6.99M | Jul 27, 2026 |
| MOMTAZEE JAMES CDirector | Grant | 405 | — | — | Jul 17, 2026 |
| OREN ILANDirector | Grant | 775 | — | — | Jul 17, 2026 |
| EPPERLY MELISSA BDirector | Grant | 543 | — | — | Jul 17, 2026 |
| FITZGERALD MEGHANDirector | Exercise | 10.0k | $8.80 | $88k | Jun 30, 2026 |
| GOLD DANIEL ALLENDirector | Sellindirect | 1.44M | $33.92 | $49.35M | Jun 30, 2026 |
| MANCHESTER KEITH SDirector | Sell | 1.64M | $33.92 | $56.44M | Jun 30, 2026 |
| FITZGERALD MEGHANDirector | Sell | 10.0k | $34.90 | $349k | Jun 30, 2026 |
| EPPERLY MELISSA BDirector | Exercise | 17.8k | $4.46 | $79k | Jun 29, 2026 |
| EPPERLY MELISSA BDirector | Sell | 17.8k | $34.32 | $610k | Jun 29, 2026 |
| SUKHATME MAYUKHPresident | Exercise | 1.00M | $3.85 | $3.85M | Jun 26, 2026 |
| SUKHATME MAYUKHPresident | Sell | 1.00M | $34.08 | $34.10M | Jun 26, 2026 |
| VENKER ERICPresident | Exercise | 200.0k | $3.85 | $770k | Jun 24, 2026 |
No analyst notes on ROIV yet.
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 9 | 1 | 0 | 0 | Buy1.92 |
| 1 mo ago | 2 | 9 | 1 | 0 | 0 | Buy1.92 |
| 2 mo ago | 2 | 9 | 1 | 0 | 0 | Buy1.92 |
| 3 mo ago | 2 | 10 | 1 | 0 | 0 | Buy1.92 |